Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Applied Genetic Technologies Corp.
  • Argos Therapeutics Inc.
  • Can-Fite BioPharma Ltd.
  • Celator Pharmaceuticals Inc.
  • Concert Pharmaceuticals
  • CTI BioPharma
  • Cytori Therapeutics Inc.
  • DelMar Pharmaceuticals Inc.
  • Dendreon Corp.
  • Flex Pharma
  • Galena Biopharma Inc.
  • GenVec Inc.
  • ImmunoCellular Therapeutics Ltd.
  • Lion Biotechnologies
  • MEI Pharma Inc.
  • OncoSec Medical Inc.
  • Oncothyreon Inc.
  • Paratek Pharmaceuticals Inc.
  • Peregrine Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • ROTH Capital Partners
  • Stemline Therapeutics Inc.
  • Sunesis Pharmaceuticals Inc.
  • Synta Pharmaceuticals Corp.
  • TG Therapeutics Inc.
  • Threshold Pharmaceuticals Inc.
  • Verastem Inc.
  • Viralytics Ltd.
  • Zosano Pharma Corp.
  • ZZ-OLD Lion Biotechnologies Inc.

Joseph Pantginis

ROTH Capital Partners

Image: Joseph Pantginis

Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining ROTH, Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JBHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co. Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.




Recent Interviews

Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners (6/17/15) The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors can find gems. Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make some of these tiny companies move up the ladder in market valuation. In this interview with The Life Sciences Report, Pantginis discusses five names with development programs capable of generating dramatic growth.

A Bull Run Hiccup: 2015 Small-Cap Biotech Watchlist Update (5/13/15) It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance.

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15) For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

Recent Quotes

"We believe that CPXX's CPX-351 has significantly more room to grow." (6/24/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older." (6/17/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >

"RNN is playing in the right space of targeted therapies." (6/17/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >

"IMUC is a very intriguing name." (6/17/15) ImmunoCellular Therapeutics Ltd. - The Life Sciences Report Interview with Joe Pantginis More >

"CPXX is improving the current standard of care in acute myeloid leukemia." (6/17/15) Celator Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >

"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better." (6/17/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Joe Pantginis More >

"We believe SNSS' subgroup analyses could be meaningful to regulators." (6/15/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CPXX announced expansion of one cohort in the MDS/AML CPX-351 study." (6/8/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

more comments

"CPXX's Phase 3 data release this month represents a major catalyst." (6/3/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The recent resurgence of CANF's psoriasis program is encouraging." (5/31/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"In SNSS' VALOR study, subgroups showed improved overall survival." (5/21/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"SNSS is targeting its formal meeting with the FDA in mid-2015 and, if successful, a rolling NDA submission in H2/15." (5/13/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Joe Pantginis More >

"We believe the RNN story is prepped for success." (5/11/15) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The induction CR/CRi rate later in Q2/15 is a major catalyst for CPXX." (5/7/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"SNSS targets meeting with the FDA and the EMA in mid-2015." (5/5/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"Important background activities continue at SNSS." (4/27/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CANF announced it will resume its psoriasis program for CF101." (4/27/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"CANF's agreement with Cipher validates the commitment to CF101." (3/23/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"CANF completed development of the commercial biomarker test for A3AR." (3/18/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"RNN's Phase 1 Supinoxin and RX-3117 studies wrap up around mid-2015." (3/17/15) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"This year should be a turning point for IMUC, so we reiterate our Buy rating." (3/13/15) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"We see upside for SNSS shares in 2015." (3/13/15) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We believe 2015 will see a flurry of activity out of DMPI." (2/18/15) DelMar Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CANF's Phase 2/3 study of CF101 in plaque psoriasis patients is complete; we believe now is a good time to buy." (2/4/15) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"We have high confidence in CPXX's CPX-351, which meets a continuing unmet medical need." (1/20/15) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"SNSS shares should perform well in 2015." (12/15/14) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our Buy rating for CPXX." (12/8/14) Celator Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"DMPI has a valuable, novel asset with distinguishing attributes." (11/17/14) DelMar Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"65% of the target group for IMUC's ICT-107 Phase 2 trial are alive compared to 50% in the control group." (11/14/14) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"In Q3/14, SNSS reported EPS of $0.25, beating our estimate and the consensus." (11/11/14) Sunesis Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The FDA gave orphan status to RNN's RX-3117 for pancreatic cancer." (9/24/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We see significant partnering potential for CANF's rheumatoid arthritis drug." (9/2/14) Can-Fite BioPharma Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"The RNN story can now be viewed as a ground floor opportunity." (8/14/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The RNN story can now be viewed as an emerging opportunity." (7/18/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"RNN's RX-3117 has potential to be a sleeper product candidate." (6/5/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"We initiate coverage on RNN with a Buy rating." (1/9/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"Japan's new Regenerative Medicine Law is positive for CYTX." (11/21/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"We are encouraged by CYTR's preliminary response data for the first-line sarcoma study." (9/30/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is a leading regenerative medicine player." (9/20/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is poised for significant cash flow and its cardiovascular pipeline holds promise." (9/10/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We maintain our Buy rating on CYTR; investors should own shares." (8/6/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We believe that IMUC is well positioned to become a leading player in the cancer immunotherapy space." (7/30/13) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

fewer comments


Due to permission requirements, not all quotes are shown.